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OBJECTIVES: Treprostinil is available in two forms (inhaled vs. infused) for the
treatment of patients with pulmonary arterial hypertension (PAH) and New York
Heart Association (NYHA) Class II-IV symptoms. The preference from 384 members
of the general public for the inhaled form, and this population’s willingness-to-pay
(WTP) in additional monthly insurance premiums for the inclusion of this treat-
ment on a hypothetical insurance scheme have been previously reported. The
present cost-benefit analysis (CBA) explored whether it would be cost-beneficial to
include inhaled treprostinil to a list of medications reimbursed by private third-
party payers in Canada, for PAH NYHA Class III patients. METHODS: The CBA was
based on a hypothetical population of 100,000. Total yearly benefits were calculated
by targeting subjects 18 years of age or older and active in the workforce, applying
the percentage of subjects who prefer inhaled treprostinil to infused treprostinil
(85.8%) and their median monthly WTP ($CAD21.50) multiplied by 12. Potential
costs were evaluated by estimating the number of potential PAH patients in the
hypothetical cohort, 18 years of age or older and in NYHA Class III category, mul-
tiplied by the annual cost of using inhaled treprostinil ($117,893). The final cost-
benefit to third-party payers was appraised by subtracting the potential costs from
the potential benefits. RESULTS: Based on prevalence rates, the hypothetical start-
ing cohort would yield 2 patients, resulting in expected costs of $235,786 to third-
party payers. The estimated number of subjects willing to pay for the inclusion of
inhaled treprostinil on the formulary of reimbursed drugs was 37,540, generating
benefits of $9,685,320. Hence, the expected difference (benefits minus costs) was
$9,449,534. CONCLUSIONS: The inclusion of inhaled treprostinil to formularies of
reimbursed medications would be highly cost-beneficial to private third-party pay-
ers in the province of Ontario, Canada, for patients with PAH and NYHA Class III
symptoms.
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OBJECTIVES: Fixed combinations of inhaled corticosteroids and long-acting 2-
agonists are widely used in treatment of patients with chronic obstructive pulmo-
nary disease (COPD) to reduce exacerbations. Cost-effectiveness analyses compar-
ing the costs and effects of the fixed combinations budesonide/formoterol and
fluticasone/salmeterol in COPD are scarce. The objective of this study was to eval-
uate the cost-effectiveness of budesonide/formoterol relative to fluticasone/sal-
meterol based on up to eleven years of real-world effectiveness data (NCT01146392)
from a Swedish health care perspective. METHODS: Resource use and effective-
ness data were collected retrospectively from primary care medical records’ data,
patients 18 years, both sexes, with a diagnosis of COPD (J44) and merged with
Swedish hospital, drug, and cause of death register data from 1 January 1999 to 31
December 2009. Propensity score matching of treatment groups was done at the
index date (first prescription of fixed combination post COPD diagnosis). Exacerba-
tions were defined as hospitalisations and emergency room visits for COPD, pre-
scription of glucocorticosteroids and/or prescription of antibiotics for respiratory
tract infections. Annual exacerbation rates were calculated using Poisson regres-
sion. The effectiveness variable was the number of exacerbations avoided. Direct
costs were calculated by applying year 2010 Swedish unit costs to the annual re-
source use. Bootstrapping was used to quantify uncertainty around estimates.
RESULTS: Based on 2734 patients in each treatment group, the annual exacerba-
tion rate was 0.800 for patients treated with budesonide/formoterol and 1.090 for
patients treated with fluticasone/salmeterol (26.6% reduction, p0.0001). Treat-
ment with budesonide/formoterol was found to be cost-saving compared with
treatment with fluticasone/salmeterol (total average annual per patient cost of
SEK12 580 [€1318] and SEK15 979 [€1675], respectively). CONCLUSIONS: Budes-
onide/formoterol was the dominant strategy (more effective at lower cost) com-
pared to fluticasone/salmeterol for the treatment of patients with COPD based on
11 years of real-world effectiveness data.
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OBJECTIVES: To estimate the cost-effectiveness of Beclomethasone/Formoterol
(BF) versus Fluticasone/Salmeterol (FS) in the treatment of adult out-patients with
moderate to severe asthma from the perspective of the Society in Spain.
METHODS: A Markov model was developed with five asthma health states: suc-
cessful control, sub-optimal control, outpatient-managed exacerbation, inpatient-
managed exacerbation, and death. Weekly transition probabilities were derived
from the published 12-weeks ICAT SE study. Resources utilization were obtained
from a published Spanish study designed ad-hoc to ascertain health care resources
utilization, the so-called lost-workday-equivalents, and corresponding costs re-
lated with treatment of asthma in the year 2011. Time horizon was set at 12 weeks
in the basecase scenario. Effectiveness was expressed as quality-adjusted life years
(QALY) gain. The cost-effectiveness was expressed as an incremental cost effec-
tiveness ratio (ICER). Bootstrapping techniques (10,000 re-samples) were used to
obtain the probabilistic ICER, its 95% percentile confidence interval (CI) and the
cost-effectiveness acceptability curve. Univariate and probabilistic sensitivity
analysis (PSA) were also applied and included, among others, extension of the
horizon to one year and the perspective of the NHS only. RESULTS: Compared with
FS, BF was associated with a slightly increase in QALY gain; 0,7974 vs. 0,7945 while
differential costs were always lower favoring BF and yielding to a mean ICER dom-
inant (95% CI: dominant; €46,930) per QALY gained. In 96% of re-samples, the ICER
was below the threshold of €30,000 per QALY, considered as cost-effective in Spain.
Univariate and PSA were robust and confirmed results of the basecase scenario.
CONCLUSIONS: From the Spanish societal and NHS perspectives in year 2011,
Becomethasone/Formoterol produced similar QALY gain at a lower cost when com-
pared with Fluticasone/Salmeterol in a highly meaningful number of replications
and scenarios. Thus, Beclomethasone/Formoterol may be considered a cost-effec-
tive alternative in the treatment of moderate to severe asthma in Spain.
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OBJECTIVES: To conduct comparative pharmacoeconomic analysis of
roflumilastformoterol versus formoterol monotherapy in adult patients with se-
vere-to-very severe COPD. METHODS: Analysis of the published clinical trials was
conducted to evaluate comparative efficacy and safety of the studied therapy op-
tions. Expected difference in direct medical costs was calculated in Excel model
based on clinical trial data about decreased number of exacerbations on
roflumilastformoterol therapy. 1-year costs of treatment were calculated from
the Russian health care system point of view. Parameter uncertainty was explored
using one-way sensitivity analysis. RESULTS: Patients on combination therapy
have 20.7% less exacerbations that leads to decreased costs of treatment. The
annual treatment cost per 1 patient was 37.93 USD less for roflumilastformoterol
therapy than for formoterol. The one-way sensitivity analysis showed that the
results are sensitive to the variations of key model parameters: for example com-
bination therapy remained the cheaper alternative when the price for roflumilast
was no more than  5.0-5.2% from the basic level. CONCLUSIONS: The combina-
tion of roflumilast  formoterol on average was more effective and cost-saving
treatment option for patients with severe-to-very severe COPD, but the results are
sensitive to the variations of price of roflumilast, the length of stay costs and the
duration of hospital stay for COPD exacerbations.
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OBJECTIVES: Austria’s smoking-rate is among the world highest. Varenicline has
been shown to be an effective and well-tolerated intervention for smoking cessa-
tion. The objective of this study was to evaluate and compare the cost-effective-
ness of varenicline with bupropion and nicotine-replacement-therapy (NRT) for
smoking cessation in Austria. METHODS: A markov-model was used to demon-
strate the Benefits of Smoking Cessation on Outcomes (BENESCO model). The
model simulates the incidence of four smoking-related morbidities: lung-cancer,
chronic-obstructive-pulmonary-disease, coronary-heart-disease and stroke. The
model computes costs, quality-adjusted-life-years (QALYs) and life-years (LYs)
gained. Incremental cost-utility-ratios were calculated, adopting a lifetime per-
spective. Efficacy data were obtained from a pooled varenicline phase 3a studies
(22.5% for varenicline and 15.7% for bupropion) and from Silagy(2005) for NRT
(15.5%). QALYs, life-years and costs were discounted at 5% p.a. RESULTS: The anal-
yses imply that for Austria, smoking cessation using varenicline versus budropion
or NRT is associated with reduced smoking-related morbidity and mortality. The
number of morbidities and mortalities avoided over lifetime, per 1000 smokers
attempting to quit, amounts to 7.36 cases of morbidities and 4.14 deaths if vareni-
cline is used instead of bupropion and 7.40 morbidities and 4.14 mortalities when
varenicline is used in place of NRT. The number of QALYs gained over lifetime, per
1000 smokers, was 16.64 (15.32 LYs gained) in case of varenicline vs. bupropion and
16.74 QALYs gained (15.40 LYs gained) for varenicline vs. NRT. The incremental
cost-utility-ratio of varenicline vs. bupropion amounts to 5,367€ and for varenicline
vs. NRT it is 4,070€. Additional costs were paid out-of-pocket. Probabilistic-sensi-
tivity-analyses demonstrated the robustness of the model regarding assumptions
and input-parameters. CONCLUSIONS: This cost-effectiveness analysis demon-
strated that varenicline treatment is cost-effective in Austria. Our results suggest
that funding varenicline as a smoking cessation aid is justifiable from a health care
resource allocation perspective.
PRS25
COST ANALYSIS OF OMALIZUMAB USE IN PATIENTS WITH SEVERE
UNCONTROLLED ASTHMA WITHIN THE MEXICAN PUBLIC HEALTH CARE
SYSTEM
Lemus-Carmona E1, Reyes-Lopez A2, Jimenez Aranda P3
1Novartis Pharmaceuticals Corporation, Mexico City, Mexico, 2Mexican Children Hospital, Mexico
City, Mexico, 3Novartis, Coyoacan, Mexico
A563V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) A 2 7 7 – A 5 7 5
